We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dionex to Purchase ESA Biosciences' HPLC Assets

By LabMedica International staff writers
Posted on 18 Sep 2009
Dionex Corporation (Sunnyvale, CA, USA), a provider of liquid chromatography analysis systems, has entered into an asset purchase agreement with ESA Biosciences (Chelmsford, MA, USA), a wholly owned subsidiary of Magellan Biosciences, Inc. More...
Dionex will purchase ESA Biosciences high performance liquid chromatography (HPLC) products, HPLC clinical assays, and laboratory services.

The agreement will give Dionex three lines of HPLC detectors. These products include the Corona universal charged aerosol detectors, which Dionex will sell with its own HPLC equipment or directly on third party systems. The other two product lines, the CoulArray and Coulocheme electrochemical detectors are targeted at clinical, metabolomics, and neuroscience applications.

Combined with Dionex expertise in electrochemistry detection for carbohydrates and glycobiology, this acquisition will position it as a leading provider of comprehensive electrochemistry solutions for liquid chromatography.

The terms of the transaction were not disclosed. Dionex anticipates that the transaction will generate additional revenue of US$12-$15 million and excluding one time charges will be slightly accretive in fiscal 2010. The transaction is expected to close by the end of September 2009.

Dionex is a manufacturer and marketer of ion chromatography, HPLC and sample preparation systems, accessories and consumables, and software products for chemical and life sciences applications. Dionex provides application solutions ranging from the identification and measurement of inorganic and organic ions, small organic molecules, as well as large biomolecules.

ESA Biosciences designs and manufactures a full range of specialty detectors, reagents, and total solutions. The products are used in neuroscience, clinical diagnostic, biomedical research, and industrial laboratories worldwide. Through its subsidiary, ESA Laboratories, Inc., the company also provides a range of analytical services ranging from industrial hygiene and clinical diagnostic analysis, to metabolomics profiling.

Related Links:

Dionex Corporation
ESA Biosciences



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.